Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study
Andre, T. Falcone, A. Shparyk, Y. V. Moiseenko, F. V. Polo, E. Csoszi, T. Bragagnoli, A. S. C. Liposits, G. Chmielowska, E. Delaporte, F.
Andre, T.
Falcone, A.
Shparyk, Y. V.
Moiseenko, F. V.
Polo, E.
Csoszi, T.
Bragagnoli, A. S. C.
Liposits, G.
Chmielowska, E.
Delaporte, F.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Andre T, Falcone A, Shparyk YV, Moiseenko FV, Polo E, Csoszi T, et al. Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000717.